Artelo Biosciences, Inc.

ARTL Nasdaq SEC CIK 1621221
Follow Artelo Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$1.8M +43.3% vs same quarter last year
EPS, diluted −$3.19
Operating cash flow −$2.6M +25% vs same quarter last year
Operating income −$1.8M +42% vs same quarter last year
Net income by quarter
−$3.8M
−$2.4M
−$3.2M
−$3.1M
−$4.2M
−$3M
−$2.4M
−$1.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
−$15M−$10M−$5M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$12.9M
FY24−$9.8M
FY23−$9.3M
FY22−$10.1M
FY21−$7.4M
FY20−$4.7M
FY19−$2.2M
FY18−$2.3M
FY17−$234.9K
FY16−$29.7K
FY15−$15.2K
FY14−$15.3K